These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 37872660)

  • 1. CXCR5 + CD8 + T Cell-mediated Suppression of Humoral Alloimmunity and AMR in Mice Is Optimized With mTOR and Impaired With Calcineurin Inhibition.
    Han JL; Zimmerer JM; Zeng Q; Chaudhari SR; Hart M; Satoskar AA; Abdel-Rasoul M; Breuer CK; Bumgardner GL
    Transplantation; 2024 Mar; 108(3):679-692. PubMed ID: 37872660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. mTOR Inhibition Suppresses Posttransplant Alloantibody Production Through Direct Inhibition of Alloprimed B Cells and Sparing of CD8+ Antibody-Suppressing T cells.
    Avila CL; Zimmerer JM; Elzein SM; Pham TA; Abdel-Rasoul M; Bumgardner GL
    Transplantation; 2016 Sep; 100(9):1898-906. PubMed ID: 27362313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-Suppressor CXCR5+CD8+ T Cells Are More Potent Regulators of Humoral Alloimmunity after Kidney Transplant in Mice Compared to CD4+ Regulatory T Cells.
    Han JL; Zimmerer JM; Zeng Q; Chaudhari S; Satoskar A; Abdel-Rasoul M; Uwase H; Breuer CK; Bumgardner GL
    J Immunol; 2024 May; 212(9):1504-1518. PubMed ID: 38517294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-suppressor CXCR5
    Zimmerer JM; Han JL; Peterson CM; Zeng Q; Ringwald BA; Cassol C; Chaudhari S; Hart M; Hemminger J; Satoskar A; Abdel-Rasoul M; Wang JJ; Warren RT; Zhang ZJ; Breuer CK; Bumgardner GL
    Am J Transplant; 2022 Jun; 22(6):1550-1563. PubMed ID: 35114045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mammalian Target of Rapamycin Inhibitors Combined With Calcineurin Inhibitors as Initial Immunosuppression in Renal Transplantation: A Meta-analysis.
    Montero N; Quero M; Melilli E; Pérez-Sáez MJ; Redondo-Pachón D; Bestard O; Crespo M; Cruzado JM; Pascual J
    Transplantation; 2019 Oct; 103(10):2031-2056. PubMed ID: 31343574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different in vitro proliferation and cytokine-production inhibition of memory T-cell subsets after calcineurin and mammalian target of rapamycin inhibitors treatment.
    Merino D; San Segundo D; Medina JM; Rodrigo E; Asensio E; Irure J; Fernández-Fresnedo G; Arias MA; López-Hoyos M
    Immunology; 2016 Jun; 148(2):206-15. PubMed ID: 26931075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conversion From Calcineurin to Mammalian Target of Rapamycin Inhibitors in Liver Transplantation: A Meta-Analysis of Randomized Controlled Trials.
    Glover TE; Watson CJ; Gibbs P; Bradley JA; Ntzani EE; Kosmoliaptsis V
    Transplantation; 2016 Mar; 100(3):621-9. PubMed ID: 26636736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effector Antitumor and Regulatory T Cell Responses Influence the Development of Nonmelanoma Skin Cancer in Kidney Transplant Patients.
    Crespo E; Fernandez L; Lúcia M; Melilli E; Lauzurica R; Penin RM; Quer A; Luque S; Quero M; Manonelles A; Torras J; Cruzado JM; Cañas L; Grinyó JM; Bestard O
    Transplantation; 2017 Sep; 101(9):2102-2110. PubMed ID: 28403126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conversion From Calcineurin Inhibitors to Mammalian Target of Rapamycin Inhibitors in Kidney Transplant Recipients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Zeng J; Zhong Q; Feng X; Li L; Feng S; Fan Y; Song T; Huang Z; Wang X; Lin T
    Front Immunol; 2021; 12():663602. PubMed ID: 34539621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcineurin Inhibitor Minimization With Ixazomib, an Investigational Proteasome Inhibitor, for the Prevention of Antibody Mediated Rejection in a Preclinical Model.
    Reese SR; Wilson NA; Huang G; Redfield RR; Zhong W; Djamali A
    Transplantation; 2015 Sep; 99(9):1785-95. PubMed ID: 25919767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients.
    Karpe KM; Talaulikar GS; Walters GD
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD006750. PubMed ID: 28730648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological Results of Long-Term Use of Mammalian Target of Rapamycin (mTOR) Inhibitors and Its Effects on Renal Graft Functions.
    Tanrısev M; Ayna Kılıçaslan T; Çolak H; Ersan S; Yılmaz B; Alp A; Tuğmen C; Sevgili BE
    Ann Transplant; 2021 Sep; 26():e932434. PubMed ID: 34531361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-suppressor CD8+ T Cells Require CXCR5.
    Zimmerer JM; Ringwald BA; Elzein SM; Avila CL; Warren RT; Abdel-Rasoul M; Bumgardner GL
    Transplantation; 2019 Sep; 103(9):1809-1820. PubMed ID: 30830040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. mTOR inhibitors and risk of chronic antibody-mediated rejection after kidney transplantation: where are we now?
    Grimbert P; Thaunat O
    Transpl Int; 2017 Jul; 30(7):647-657. PubMed ID: 28445619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients.
    Lim WH; Eris J; Kanellis J; Pussell B; Wiid Z; Witcombe D; Russ GR
    Am J Transplant; 2014 Sep; 14(9):2106-19. PubMed ID: 25088685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An mTOR-inhibitor-based protocol and calcineurin inhibitor (CNI)-free treatment in kidney transplant recipients from donors after cardiac death: good renal function, but high incidence of conversion to CNI.
    Sánchez-Escuredo A; Diekmann F; Revuelta I; Esforzado N; Ricart MJ; Cofán F; Torregrosa JV; Peri L; Ruiz Á; Campistol JM; Oppenheimer F
    Transpl Int; 2016 Mar; 29(3):362-8. PubMed ID: 26678359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of De Novo mTOR Inhibitors in Hypersensitized Kidney Transplant Recipients: Experience From Clinical Practice.
    Cucchiari D; Molina-Andujar A; Montagud-Marrahi E; Revuelta I; Rovira J; Ventura-Aguiar P; Piñeiro GJ; De Sousa-Amorim E; Esforzado N; Cofán F; Torregrosa JV; Ugalde-Altamirano J; Ricart MJ; Centellas-Pérez FJ; Solè M; Martorell J; Ríos J; Campistol JM; Diekmann F; Oppenheimer F
    Transplantation; 2020 Aug; 104(8):1686-1694. PubMed ID: 32732848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relative Frequencies of Alloantigen-Specific Helper CD4 T Cells and B Cells Determine Mode of Antibody-Mediated Allograft Rejection.
    Alsughayyir J; Chhabra M; Qureshi MS; Mallik M; Ali JM; Gamper I; Moseley EL; Peacock S; Kosmoliaptsis V; Goddard MJ; Linterman MA; Motallebzadeh R; Pettigrew GJ
    Front Immunol; 2018; 9():3039. PubMed ID: 30740108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medical Aspects of mTOR Inhibition in Kidney Transplantation.
    Cuadrado-Payán E; Diekmann F; Cucchiari D
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Immunosuppressive Treatment on Carotid Atherosclerosis in Renal Transplant Recipients.
    Szymczak M; Kluz J; Małecki R; Wątorek E; Obremska M; Głuszek M; Klinger M; Boratyńska M
    Transplant Proc; 2016 Jun; 48(5):1626-9. PubMed ID: 27496459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.